Victoria Polonis
Overview
Explore the profile of Victoria Polonis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bai H, Lewitus E, Li Y, Thomas P, Zemil M, Merbah M, et al.
Nat Commun
. 2024 May;
15(1):3924.
PMID: 38724518
An effective HIV-1 vaccine must elicit broadly neutralizing antibodies (bnAbs) against highly diverse Envelope glycoproteins (Env). Since Env with the longest hypervariable (HV) loops is more resistant to the cognate...
2.
Song H, Marichannegowda M, Setua S, Bose M, Sanders-Buell E, King D, et al.
Res Sq
. 2023 Oct;
PMID: 37841838
Nearly all transmitted/founder (T/F) HIV-1 are CCR5 (R5)-tropic. While previous evidence suggested that CXCR4 (X4)-tropic HIV-1 are transmissible, detection was not at the earliest stages of acute infection. Here, we...
3.
Wieczorek L, Peachman K, Steers N, Schoen J, Rao M, Polonis V, et al.
Virology
. 2020 Sep;
550:99-108.
PMID: 32980676
The membrane proximal external region (MPER) of HIV-1 gp41 is targeted by several neutralizing antibodies (NAbs) and is of interest for vaccine design. In this study, we identified novel MPER...
4.
Om K, Paquin-Proulx D, Montero M, Peachman K, Shen X, Wieczorek L, et al.
PLoS Pathog
. 2020 Sep;
16(9):e1008764.
PMID: 32881968
To augment HIV-1 pox-protein vaccine immunogenicity using a next generation adjuvant, a prime-boost strategy of recombinant modified vaccinia virus Ankara and multimeric Env gp145 was evaluated in macaques with either...
5.
Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Kaewkungwal J, Dawson P, Dhitavat J, et al.
Lancet HIV
. 2020 Feb;
7(4):e238-e248.
PMID: 32035516
Background: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV acquisition. In...
6.
Ake J, Schuetz A, Pegu P, Wieczorek L, Eller M, Kibuuka H, et al.
J Infect Dis
. 2017 Oct;
216(9):1080-1090.
PMID: 28968759
Background: We report the first-in-human safety and immunogenicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery by either...
7.
McLinden R, Paris R, Polonis V, Close N, Su Z, Shikuma C, et al.
AIDS
. 2012 Jul;
26(11):1452.
PMID: 22767347
No abstract available.
8.
Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, et al.
PLoS One
. 2012 May;
7(5):e36438.
PMID: 22590544
Background: Neutralizing antibodies provide markers for vaccine-induced protective immunity in many viral infections. By analogy, HIV-1 neutralizing antibodies induced by immunization may well predict vaccine effectiveness. Assessment of neutralizing antibodies...
9.
Matyas G, Wieczorek L, Bansal D, Chenine A, Sanders-Buell E, Tovanabutra S, et al.
Biochem Biophys Res Commun
. 2010 Nov;
402(4):808-12.
PMID: 21040700
A murine IgG mAb, WR321, selected for the ability to bind to phosphatidylinositol-4-phosphate and phosphatidylinositol-4,5-bisphosphate, but an inability to bind to any of 17 other lipids, including phosphatidylinositol, was examined...
10.
Edmonds T, Ding H, Yuan X, Wei Q, Smith K, Conway J, et al.
Virology
. 2010 Sep;
408(1):1-13.
PMID: 20863545
Effective vaccine development for human immunodeficiency virus type 1 (HIV-1) will require assays that ascertain the capacity of vaccine immunogens to elicit neutralizing antibodies (NAb) to diverse HIV-1 strains. To...